phrykt

Ultragenyx Pharmaceutical Inc. (RARE): who owns it and who trades it

As of Nov 16, 2026, RARE insiders reported 28 open-market sales worth $3.8M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Emil D Kakkis (CEO), with $1.2M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Ultragenyx Pharmaceutical

From the latest filings

Overall: more buying than selling. Insiders mostly sold. Famous investors and Congress mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns RARE

311 funds and institutions reported RARE shares worth $3.7B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 10.8%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.10.8%
Rtw Investments, LP7.9%
Vanguard Portfolio Management LLC6.9%
AQR Capital Management LLC6.7%
State Street Corp6.3%
Vanguard Capital Management LLC4.4%
Two Sigma Investments, LP3.7%
California State Teachers Retirement System3.4%
Sands Capital Management, LLC3.2%
Jacobs Levy Equity Management, Inc3.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.10.65M10.82%$356M+46%
Rtw Investments, LP7.80M7.92%$260M+114%
Vanguard Portfolio Management LLC6.79M6.89%$227M+26%
AQR Capital Management LLC6.56M6.66%$214M+43%
State Street Corp6.16M6.25%$206M+23%
Vanguard Capital Management LLC4.30M4.36%$143M+3%
Two Sigma Investments, LP3.62M3.68%$121M+64%
California State Teachers Retirement System3.39M3.44%$101M+3138%
Sands Capital Management, LLC3.16M3.21%$105M-2%
Jacobs Levy Equity Management, Inc2.94M2.98%$98.2M+105%
Frontier Capital Management Co LLC2.85M2.89%$95.1M+30%
Geode Capital Management, LLC2.58M2.62%$86.1M+39%
Bellevue Group AG1.98M2.01%$66.2M-17%
D. E. Shaw & Co., Inc.1.73M1.76%$57.8M+37%
Sofinnova Investments, Inc.1.72M1.74%$57.3M-45%
Adage Capital Partners Gp, L.l.c.1.58M1.60%$52.8M+229%
GW&K Investment Management, LLC1.48M1.50%$49.5M-8%
Mpm Bioimpact LLC1.42M1.44%$47.4M–
T. Rowe Price Associates1.36M1.38%$45.3M+69%
Morgan Stanley1.32M1.35%$44.2M-12%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, RARE insiders reported $0 of open-market purchases and $3.8M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$3.8M
28 trades, 9 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Oct 15, 2026
Filed Oct 19, 2026

Purchases and sales by month

$2.5M$2.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 15, 2026Howard HornCFOSale7,066$15.27$108KForm 4
Sep 15, 2026Theodore Alan HuizengaVice presidentSale1,283$13.57$17.4KForm 4
Sep 3, 2026Theodore Alan HuizengaVice presidentSale161$13.99$2.3KForm 4
Aug 3, 2026Karah Herdman ParschauerVice presidentSale1,900$24.92$47.3KForm 4
Aug 3, 2026Howard HornCFOSale4,696$24.92$117KForm 4
Jul 1, 2026Howard HornCFOSale4,698$33.13$156KForm 4
Jun 15, 2026Corazon (Corsee) D. SandersDirectorSale2,000$25.05$50.1KForm 4
Jun 15, 2026Karah Herdman ParschauerVice presidentSale1,899$24.62$46.8KForm 4
Jun 1, 2026Howard HornCFOSale4,653$23.77$111KForm 4
May 18, 2026Shehnaaz SulimanDirectorSale5,740$25.12$144KForm 4
May 5, 2026Eric CrombezVice presidentSale344$24.96$8.6KForm 4
May 1, 2026Howard HornCFOSale4,683$24.90$117KForm 4
Apr 1, 2026Howard HornCFOSale4,683$20.97$98.2KForm 4
Mar 10, 2026Karah Herdman ParschauerVice presidentSale3,508$22.67$79.5KForm 4
Mar 6, 2026Karah Herdman ParschauerVice presidentSale6,018$21.40$129KForm 4
Mar 3, 2026Howard HornCFOSale1,635$22.40$36.6KForm 4
Mar 2, 2026John Richard PinionSee RemarksSale10,029$22.80$229KForm 4
Mar 2, 2026Erik HarrisVice presidentSale10,539$22.80$240KForm 4
Mar 2, 2026Emil D KakkisCEOSale54,404$22.80$1.2MForm 4
Mar 2, 2026Karah Herdman ParschauerVice presidentSale8,135$22.80$185KForm 4
Mar 2, 2026Theodore Alan HuizengaVice presidentSale1,632$22.80$37.2KForm 4
Mar 2, 2026Howard HornCFOSale5,290$22.80$121KForm 4
Mar 2, 2026Howard HornCFOSale3,119$22.54$70.3KForm 4
Mar 2, 2026Eric CrombezVice presidentSale7,029$22.80$160KForm 4
Feb 2, 2026Howard HornCFOSale3,061$23.56$72.1KForm 4
Jan 2, 2026Howard HornCFOSale3,150$22.84$71.9KForm 4
Dec 29, 2025Theodore Alan HuizengaVice presidentSale85$34.38$2.9KForm 4
Dec 10, 2025Howard HornCFOSale3,081$36.38$112KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Emil D KakkisPresident & CEO, Director–$1.2MMar 2, 2026
Howard HornChief Financial Officer–$1.2MOct 15, 2026
Karah Herdman ParschauerEVP and Chief Legal Officer–$488KAug 3, 2026
Erik HarrisEVP & Chief Commercial Officer–$240KMar 2, 2026
John Richard PinionSee Remarks–$229KMar 2, 2026
Eric CrombezEVP and Chief Medical Officer–$169KMay 5, 2026
Shehnaaz SulimanDirector–$144KMay 18, 2026
Theodore Alan HuizengaSVP, Chief Accounting Officer–$59.8KSep 15, 2026
Corazon (Corsee) D. SandersDirector–$50.1KJun 15, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RARE short interest

Very high short interest. 23.2% of RARE shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 69%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 23.62M RARE shares were sold short, 23.2% of the shares outstanding, up 17.3% from the report before. At the average daily volume of 2.86M shares, buying them all back would take about 8.3 trading days (days to cover).

Shares short, % of all shares

23.2%May 15Oct 3024.6%

Days to cover

8.3May 15Oct 3011.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202623.62M23.18%+17%2.86M8.3
Oct 15, 202620.15M20.43%-1%3.89M5.2
Sep 30, 202620.35M20.64%+23%6.50M3.1
Sep 15, 202616.57M16.81%-3%7.46M2.2
Aug 31, 202617.14M17.39%+8%2.14M8.0
Aug 14, 202615.89M16.12%+6%2.04M7.8
Jul 31, 202614.96M15.18%+11%1.81M8.3
Jul 15, 202613.44M13.64%-17%1.94M6.9
Jun 30, 202616.22M16.47%+13%4.50M3.6
Jun 15, 202614.31M14.53%-3%1.62M8.8
May 29, 202614.70M14.93%+5%1.50M9.8
May 15, 202613.98M14.19%+2%1.70M8.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded RARE

Since Nov 17, 2024, 1 member of Congress reported 5 purchases and 0 sales of RARE. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Sep 29, 2026, reported Oct 12, 2026.

Purchases 5Sales 0

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Sep 29, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfOct 12, 2026Report
Mar 3, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfApr 7, 2026Report
Feb 18, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfMar 9, 2026Report
Aug 8, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfSep 12, 2025Report
Jul 15, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfAug 14, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Ultragenyx Pharmaceutical company events

Ultragenyx Pharmaceutical filed 21 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, job cuts). The latest was on Nov 3, 2026.

  1. Nov 3, 2026DealUltragenyx Pharmaceutical Inc. completed the previously disclosed sale of its Rare Pediatric Disease Priority Review Voucher to the buyer. Filing
  2. Oct 19, 2026AnnouncementUltragenyx Pharmaceutical Inc. and Baylor Research Institute entered into a settlement agreement with Navinta LLC resolving patent litigation related to patents covering the Company’s DOJOLVI® (triheptanoin) oral liquid. Filing
  3. Oct 14, 2026AgreementUltragenyx Pharmaceutical Inc. entered into an asset purchase agreement, pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher to the buyer. Filing
  4. Oct 7, 2026AgreementUltragenyx Pharmaceutical Inc. entered into an asset purchase agreement, pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher to the buyer. Filing
  5. Sep 17, 2026AnnouncementUltragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, for the treatment of pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A). Filing
  6. Sep 2, 2026AnnouncementUltragenyx Pharmaceutical Inc. announced results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome. Filing
  7. Aug 19, 2026AnnouncementUltragenyx Pharmaceutical Inc. announced the U.S. Food and Drug Administration granted accelerated approval for GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). Filing
  8. Aug 11, 2026AnnouncementUltragenyx Pharmaceutical Inc. and Baylor Research Institute entered into a settlement agreement with Esjay Pharma Private Limited and Esjay Pharma LLC (collectively, “Esjay”) resolving patent litigation related to the Company’s DOJOLVI® (triheptanoin) oral liquid. Filing
  9. Aug 4, 2026ResultsReleased financial results. Filing
  10. May 18, 2026LeadershipAs reported below, at its Annual Meeting of Stockholders on May 14, 2026, the stockholders of Ultragenyx Pharmaceutical Inc. approved the Third Amended and Restated 2023 Incentive Plan. Filing
  11. May 5, 2026ResultsReleased financial results. Filing
  12. Apr 2, 2026AnnouncementUltragenyx Pharmaceutical Inc. issued a press release announcing that the U.S. Food and Drug Administration has accepted for review the Company’s resubmitted Biologics License Application seeking accelerated approval for UX111 (rebisufligene etisparvovec) AAV9 gene therapy as a treatment for… Filing
  13. Mar 30, 2026AnnouncementUltragenyx Pharmaceutical Inc. issued a press release announcing that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for UX016, an investigational small molecule prodrug of sialic acid being evaluated as a substrate replacement therapy for GNE myopathy. Filing
  14. Mar 12, 2026AnnouncementUltragenyx Pharmaceutical Inc. issued a press release announcing positive results from its Phase 3 Enh3ance study of DTX301, an investigational AAV8 gene therapy for the treatment of ornithine transcarbamylase deficiency. Filing
  15. Feb 23, 2026AnnouncementUltragenyx Pharmaceutical Inc. issued a press release announcing that the U.S. Food and Drug Administration has accepted for review the Biologics License Application seeking approval of DTX401 AAV gene therapy (pariglasgene brecaparvovec) for the treatment of Glycogen Storage Disease Type Ia (GSDIa). Filing
  16. Feb 12, 2026Job cutsAnnounced job cuts or other exit costs. Filing
  17. Feb 3, 2026AnnouncementUltragenyx Pharmaceutical Inc. issued a press release announcing new long‑term data from clinical studies evaluating UX111 (rebisufligene etisparvovec), an investigational AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), a fatal neurodegenerative lysosomal storage disorder. Filing
  18. Jan 30, 2026AnnouncementUltragenyx Pharmaceutical Inc. issued a press release announcing that that it has resubmitted its Biologics License Application seeking accelerated approval for UX111 (rebisufligene etisparvovec) AAV9 gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA) to the U.S.… Filing
  19. Jan 12, 2026ResultsReleased financial results. Filing
  20. Dec 30, 2025AnnouncementUltragenyx Pharmaceutical Inc. issued a press release announcing that that it has completed the rolling submission of its Biologics License Application to the U.S. Food and Drug Administration seeking approval for DTX401 AAV gene therapy (pariglasgene brecaparvovec) as a treatment for Glycogen… Filing
  21. Dec 29, 2025AnnouncementUltragenyx Pharmaceutical Inc. announced results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Ultragenyx Pharmaceutical financials

Famous investors that hold RARE

4 of the 50 well-known investors we track reported holding RARE in their latest 13F filing. The largest position is Israel Englander's, worth $22.8M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20261.52M$22.8M0.0%+100%
Steve Cohen · Point72 Asset ManagementQ3 2026844,410$12.7M0.0%New
Ken Griffin · Citadel AdvisorsQ3 2026356,670$5.4M0.0%+69%
Ray Dalio · Bridgewater AssociatesQ3 202657,052$857K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named RARE in the last 120 days.

FiledHolderFormStake
Nov 13, 2026AQR Capital Management, LLC13G/A0.6%
Nov 13, 2026AQR Capital Management, LLC13G/A0.6%
Nov 10, 2026STATE STREET CORPORATION13G7.6%
Nov 10, 2026STATE STREET CORPORATION13G7.6%
Oct 30, 2026Vanguard Portfolio Management13G/A8.6%
Oct 30, 2026Vanguard Portfolio Management13G/A8.6%
Oct 20, 2026Madison Avenue International LP13G6.4%
Oct 20, 2026Madison Avenue International LP13G6.4%

Questions about Ultragenyx Pharmaceutical Inc. (RARE) stock

Who owns the most RARE stock?

The largest reported owner of Ultragenyx Pharmaceutical Inc. (RARE) is BlackRock, Inc., with 10.8% of the company. In total, 311 funds and institutions reported holding RARE at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are RARE insiders buying or selling?

In the last 12 months, RARE insiders reported no open-market purchases and 28 sales worth $3.8M. The latest trade was on Oct 15, 2026. See every trade.

What is the short interest in RARE?

As of Oct 30, 2026, 23.62M RARE shares were sold short, 23.2% of the shares outstanding, up 17.3% from the report before. At the average daily volume of 2.86M shares, buying them all back would take about 8.3 trading days (days to cover). See the history.

Have members of Congress traded RARE?

Yes. 1 member of Congress reported 5 purchases and 0 sales of RARE since Nov 17, 2024. The latest was reported on Oct 12, 2026. See the trades.

Which famous investors hold RARE?

4 of the 50 well-known investors we track reported RARE in their latest 13F filing, including Israel Englander, Steve Cohen, Ken Griffin. The largest position is worth $22.8M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.